Neoadjuvant Capecitabine/Temozolomide for Locally Advanced or Metastatic Pancreatic Neuroendocrine Tumors.

Pancreas
Malcolm H SquiresJordan M Cloyd

Abstract

The combination chemotherapy regimen capecitabine/temozolomide (CAPTEM) is efficacious for metastatic well-differentiated pancreatic neuroendocrine tumors (PNETs), but its role in the neoadjuvant setting has not been established. The outcomes of all patients with locally advanced or resectable metastatic PNETs who were treated with neoadjuvant CAPTEM between 2009 and 2017 at 2 high-volume institutions were retrospectively reviewed. Thirty patients with locally advanced PNET (n = 10) or pancreatic neuroendocrine hepatic metastases (n = 20) received neoadjuvant CAPTEM. Thirteen patients (43%) exhibited partial radiographic response (PR), 16 (54%) had stable disease, and 1 (3%) developed progressive disease. Twenty-six (87%) patients underwent resection (pancreatectomy [n = 12], combined pancreatectomy and liver resection [n = 8], or major hepatectomy alone [n = 6]); 3 (18%) declined surgery despite radiographic PR, and 1 (3%) underwent aborted pancreatoduodenectomy. Median primary tumor size was 5.5 cm, and median Ki-67 index was 3.5%. Rates of PR were similar across tumor grades (P = 0.24). At median follow-up of 49 months, median progression-free survival was 28.2 months and 5-year overall survival was 63%. Neoadjuvant CAPTEM i...Continue Reading

References

Dec 1, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Maria A KouvarakiJames C Yao
Dec 3, 2011·The British Journal of Surgery·M KleineH Bektas
May 15, 2013·Journal of Gastrointestinal Surgery : Official Journal of the Society for Surgery of the Alimentary Tract·Sven-Petter HaugvikIvar Prydz Gladhaug
May 4, 2015·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Lisa-Marie DilzMarianne Pavel
May 27, 2016·The Oncologist·Robert A RamirezEugene A Woltering
Sep 17, 2016·Journal of Gastrointestinal Surgery : Official Journal of the Society for Surgery of the Alimentary Tract·Laura PrakashMatthew H G Katz
Jan 16, 2017·Journal of the American College of Surgeons·Eugene A WolteringJ Philip Boudreaux
Oct 2, 2017·HPB : the Official Journal of the International Hepato Pancreato Biliary Association·Aslam EjazTimothy M Pawlik
Oct 5, 2017·Cancer Control : Journal of the Moffitt Cancer Center·Chenwi M AmbeMokenge P Malafa
Oct 20, 2018·Journal of Gastrointestinal Surgery : Official Journal of the Society for Surgery of the Alimentary Tract·Jeffery ChakedisMary Dillhoff

❮ Previous
Next ❯

Citations

Sep 20, 2020·Annals of Surgical Oncology·Jordan M Cloyd, George A Poultsides

❮ Previous
Next ❯

Related Concepts

Related Feeds

Adenoma, Islet Cell

Islet Cell Adenoma arises in the islet cells, which are insulin producing cells of the pancreas. These tumors can be either malignant or benign. Discover the latest research on Islet Cell Adenoma here.

Carcinoma, Islet Cell

Islet Cell Carcinoma or Pancreatic Neuroendocrine Tumours arises in the hormone producing cells of the pancreas. These tumors can be either malignant or benign. Discover the latest research on Islet Cell Carcinoma here.

Carcinoma, Islet Cell (Keystone)

Islet Cell Carcinoma or Pancreatic Neuroendocrine Tumours arise in the hormone producing cells of the pancreas. These tumors can be either malignant or benign. Discover the latest research on islet cell carcinoma in this feed.